A review paper published last year in European Journal of Medicinal Chemistry characterized Myc as the “oncogene from ...

Early-onset CRC (EO-CRC) was associated with Flavonifractor plautii and increased bile acid, tryptophan, and choline ...

Carnegie Mellon University’s Summer Undergraduate Research Fellowship (SURF) program provides funding for undergraduates to work full time on research projects during the summer. Many students ...

Mutations in the oncogene KRAS are widespread in several human cancers, including pancreatic ductal adenocarcinomas (92%), colorectal carcinomas (49%) and lung adenocarcinomas (35%). These mutations ...

Verastem, Inc.'s priority PDUFA date for avutometinib + defactinib in LGSOC set for June 2025; explore future data updates. Click for my VSTM stock update.

A laboratory on Long Island has found a breakthrough in the fight against pancreatic cancer that can “intercept” its spread.

Verastem (VSTM) stock in focus as Jefferies initiates a Buy rating with a $15 target, citing a potential FDA approval for its ovarian cancer drug combo. Read more here.

Pancreatic ductal adenocarcinom a (PDAC), frequently detected at advanced stages, has a 5-year survival rate of 12%. Metastases are common, including hepatic metastasis, which is particularly lethal ...

City of Hope researchers demonstrate proof of concept for a novel targeted therapy for pancreatic cancer, exploiting transcription-replication conflicts to combat treatment resistance.

Converging computational and laboratory technologies are helping anti-cancer immune responses hit their target more ...

Caris Life Sciences has collected $168 million in new funding to support the growth of its precision medicine platforms, ...

From new KRAS and HER2 inhibitors to home-administered immunotherapy, recent trials mark a turning point in how metastatic lung cancer is managed.